Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.

The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.

The deal advances Galapagos' plan to develop a decentralized CAR T-cell therapy for non-Hodgkin lymphoma with a one-week vein-to-vein time.

The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...